Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 539 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR Making the most of your ‘eureka’ moment: getting from the science... September 22, 2021 Cure Probability Models for Evaluation of Patients with a Previous Cancer... October 26, 2021 Prognostic Role of Plasmatic BRAF Allele Fraction for Survival in Patients... March 27, 2023 FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer February 20, 2024 Load more HOT NEWS Is Proton Therapy Safer than Traditional Radiation? Tailored Radiation to Treat Brain Metastases Reduces Impact on Cognitive Function 6 Things to Know About Regrowing and Caring for Your Hair... FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer
